Yazar Araması Sonucu :: Library Catalog

1

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer Yazar: Ulka N. Vaishampayan (15051039)

Baskı/Yayın Bilgisi 2025
Diğer Yazarlar:

Favorilerime ekle

Kaydedildi:
2

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer Yazar: Ulka N. Vaishampayan (15051039)

Baskı/Yayın Bilgisi 2025
Diğer Yazarlar:

Favorilerime ekle

Kaydedildi:
3

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer Yazar: Ulka N. Vaishampayan (15051039)

Baskı/Yayın Bilgisi 2025
Diğer Yazarlar:

Favorilerime ekle

Kaydedildi:
4

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer Yazar: Ulka N. Vaishampayan (15051039)

Baskı/Yayın Bilgisi 2025
Diğer Yazarlar:

Favorilerime ekle

Kaydedildi:
5

Supplementary Table 2 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes Yazar: Justin Hwang (15925675)

Baskı/Yayın Bilgisi 2025
Diğer Yazarlar:

Favorilerime ekle

Kaydedildi:
6

Supplementary Table 1 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes Yazar: Justin Hwang (15925675)

Baskı/Yayın Bilgisi 2025
Diğer Yazarlar:

Favorilerime ekle

Kaydedildi:
7

Supplementary Figure 3 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes Yazar: Justin Hwang (15925675)

Baskı/Yayın Bilgisi 2025
Diğer Yazarlar:

Favorilerime ekle

Kaydedildi:
8

Supplementary Table 3 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes Yazar: Justin Hwang (15925675)

Baskı/Yayın Bilgisi 2025
Diğer Yazarlar:

Favorilerime ekle

Kaydedildi:
9

Supplementary Figure 1 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes Yazar: Justin Hwang (15925675)

Baskı/Yayın Bilgisi 2025
Diğer Yazarlar:

Favorilerime ekle

Kaydedildi:
10

Supplementary Figure 2 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes Yazar: Justin Hwang (15925675)

Baskı/Yayın Bilgisi 2025
Diğer Yazarlar:

Favorilerime ekle

Kaydedildi:

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer Yazar: Ulka N. Vaishampayan (15051039)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer Yazar: Ulka N. Vaishampayan (15051039)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer Yazar: Ulka N. Vaishampayan (15051039)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer Yazar: Ulka N. Vaishampayan (15051039)

Supplementary Table 2 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes Yazar: Justin Hwang (15925675)

Supplementary Table 1 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes Yazar: Justin Hwang (15925675)

Supplementary Figure 3 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes Yazar: Justin Hwang (15925675)

Supplementary Table 3 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes Yazar: Justin Hwang (15925675)

Supplementary Figure 1 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes Yazar: Justin Hwang (15925675)

Supplementary Figure 2 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes Yazar: Justin Hwang (15925675)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer Yazar: Ulka N. Vaishampayan (15051039)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer Yazar: Ulka N. Vaishampayan (15051039)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer Yazar: Ulka N. Vaishampayan (15051039)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer Yazar: Ulka N. Vaishampayan (15051039)

Supplementary Table 2 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes Yazar: Justin Hwang (15925675)

Supplementary Table 1 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes Yazar: Justin Hwang (15925675)

Supplementary Figure 3 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes Yazar: Justin Hwang (15925675)

Supplementary Table 3 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes Yazar: Justin Hwang (15925675)

Supplementary Figure 1 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes Yazar: Justin Hwang (15925675)

Supplementary Figure 2 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes Yazar: Justin Hwang (15925675)

Arama Araçları: